Achillion Pharmaceuticals (ACHN) had achieved a massive surge in stock price recently. It all started when it had reported positive data from a phase 1 study using its drug ACH-5228. This data was early, but investors were optimistic based on the initial findings of the impressive sustained responses observed in the first study. Even then, Danicopan or ACH-4471 is the first generation factor D inhibitor product that is far more advanced in the clinical process. ACH-5228 is the second generation drug that may end up being more potent. That means this biotech is